US-based Frequency Therapeutics, a clinical-stage biotechnology company creating small molecule drugs, has completed raising $42 million in its Series B funding round led by Taiwania Capital Management and Axil Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
